CD105 (Endoglin): A potential anticancer therapeutic inhibits mitogenesis and map kinase pathway activation

Donghui Liu; Shant Kumar; Jason Ashworth; Kamela Ali; Abdulmannan Fadel; Baoqiang Guo; Mark Slevin

doi:10.21873/anticanres.14879

CD105 (Endoglin): A potential anticancer therapeutic inhibits mitogenesis and map kinase pathway activation

Donghui Liu, Shant Kumar, Jason Ashworth, Kamela Ali, Abdulmannan Fadel, Baoqiang Guo, Mark Slevin

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Background: CD105 is highly expressed on human activated endothelial cells (ECs), is an important component of the TGF-β1 receptor complex and is essential for angiogenesis. CD105 expression is up-regulated in activated ECs and is an important potential marker for cancer prognosis. Materials and Methods: In vitro rat myoblasts transfected with the L-CD105 and S-CD105 transfectants. The transfectants were treated with TGF-β1 for the angiogenesis study. Results: L-CD105 affects cell proliferation in the presence and absence of TGF-β1, and inhibits p-ERK1/2, p-MEK1/2 and p-c-Jun in L-CD105 transfectants compared to controls. The induction of phospho-ERK1/2 following treatment with TGF-β1 remained significantly lower in L-CD105 transfectants compared to controls. Conclusion: L-CD105 inhibits the phosphorylation of ERK1/2, MEK1/2, c-Jun1/2/3, and associated signalling intermediates. CD105 modulates cell growth and TGF-β1 induced cell signalling through ERK-c-Jun expression.

Original language	English
Pages (from-to)	1219-1229
Number of pages	11
Journal	Anticancer Research
Volume	41
Issue number	3
DOIs	https://doi.org/10.21873/anticanres.14879
Publication status	Published - Mar 2021
Externally published	Yes

Keywords

Angiogenesis
CD105
Cell signalling
MAPK
TGF-β1

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.14879

Cite this

@article{abbdaaa267a24c5c8521dac9e124ed28,

title = "CD105 (Endoglin): A potential anticancer therapeutic inhibits mitogenesis and map kinase pathway activation",

abstract = "Background: CD105 is highly expressed on human activated endothelial cells (ECs), is an important component of the TGF-β1 receptor complex and is essential for angiogenesis. CD105 expression is up-regulated in activated ECs and is an important potential marker for cancer prognosis. Materials and Methods: In vitro rat myoblasts transfected with the L-CD105 and S-CD105 transfectants. The transfectants were treated with TGF-β1 for the angiogenesis study. Results: L-CD105 affects cell proliferation in the presence and absence of TGF-β1, and inhibits p-ERK1/2, p-MEK1/2 and p-c-Jun in L-CD105 transfectants compared to controls. The induction of phospho-ERK1/2 following treatment with TGF-β1 remained significantly lower in L-CD105 transfectants compared to controls. Conclusion: L-CD105 inhibits the phosphorylation of ERK1/2, MEK1/2, c-Jun1/2/3, and associated signalling intermediates. CD105 modulates cell growth and TGF-β1 induced cell signalling through ERK-c-Jun expression.",

keywords = "Angiogenesis, CD105, Cell signalling, MAPK, TGF-β1",

author = "Donghui Liu and Shant Kumar and Jason Ashworth and Kamela Ali and Abdulmannan Fadel and Baoqiang Guo and Mark Slevin",

year = "2021",

month = mar,

doi = "10.21873/anticanres.14879",

language = "English",

volume = "41",

pages = "1219--1229",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "3",

}

TY - JOUR

T1 - CD105 (Endoglin)

T2 - A potential anticancer therapeutic inhibits mitogenesis and map kinase pathway activation

AU - Liu, Donghui

AU - Kumar, Shant

AU - Ashworth, Jason

AU - Ali, Kamela

AU - Fadel, Abdulmannan

AU - Guo, Baoqiang

AU - Slevin, Mark

PY - 2021/3

Y1 - 2021/3

N2 - Background: CD105 is highly expressed on human activated endothelial cells (ECs), is an important component of the TGF-β1 receptor complex and is essential for angiogenesis. CD105 expression is up-regulated in activated ECs and is an important potential marker for cancer prognosis. Materials and Methods: In vitro rat myoblasts transfected with the L-CD105 and S-CD105 transfectants. The transfectants were treated with TGF-β1 for the angiogenesis study. Results: L-CD105 affects cell proliferation in the presence and absence of TGF-β1, and inhibits p-ERK1/2, p-MEK1/2 and p-c-Jun in L-CD105 transfectants compared to controls. The induction of phospho-ERK1/2 following treatment with TGF-β1 remained significantly lower in L-CD105 transfectants compared to controls. Conclusion: L-CD105 inhibits the phosphorylation of ERK1/2, MEK1/2, c-Jun1/2/3, and associated signalling intermediates. CD105 modulates cell growth and TGF-β1 induced cell signalling through ERK-c-Jun expression.

AB - Background: CD105 is highly expressed on human activated endothelial cells (ECs), is an important component of the TGF-β1 receptor complex and is essential for angiogenesis. CD105 expression is up-regulated in activated ECs and is an important potential marker for cancer prognosis. Materials and Methods: In vitro rat myoblasts transfected with the L-CD105 and S-CD105 transfectants. The transfectants were treated with TGF-β1 for the angiogenesis study. Results: L-CD105 affects cell proliferation in the presence and absence of TGF-β1, and inhibits p-ERK1/2, p-MEK1/2 and p-c-Jun in L-CD105 transfectants compared to controls. The induction of phospho-ERK1/2 following treatment with TGF-β1 remained significantly lower in L-CD105 transfectants compared to controls. Conclusion: L-CD105 inhibits the phosphorylation of ERK1/2, MEK1/2, c-Jun1/2/3, and associated signalling intermediates. CD105 modulates cell growth and TGF-β1 induced cell signalling through ERK-c-Jun expression.

KW - Angiogenesis

KW - CD105

KW - Cell signalling

KW - MAPK

KW - TGF-β1

UR - http://www.scopus.com/inward/record.url?scp=85103149133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103149133&partnerID=8YFLogxK

U2 - 10.21873/anticanres.14879

DO - 10.21873/anticanres.14879

M3 - Article

C2 - 33788713

AN - SCOPUS:85103149133

SN - 0250-7005

VL - 41

SP - 1219

EP - 1229

JO - Anticancer Research

JF - Anticancer Research

IS - 3

ER -

CD105 (Endoglin): A potential anticancer therapeutic inhibits mitogenesis and map kinase pathway activation

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this